N-(5-amino-2-methylphenyl)-2-(morpholin-4-yl)acetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(5-amino-2-methylphenyl)-2-(morpholin-4-yl)acetamide
• 英文别名: N-(5-amino-2-methylphenyl)-2-morpholinoacetamide；N-(5-amino-2-methylphenyl)-2-morpholin-4-ylacetamide
• 化学式: C₁₃H₁₉N₃O₂
• mdl: MFCD03119087
• 分子量: 249.313
• InChiKey: KETHASQTAHQNMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  67.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(5-amino-2-methylphenyl)-2-(morpholin-4-yl)acetamide 、 4-苯基苯甲酸 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以25%的产率得到N-{4-methyl-3-[(morpholin-4-ylacetyl)amino]phenyl}biphenyl-4-carboxamide
  参考文献：
  名称：

  [EN] SUBSTITUTED N-BIPHENYL-3-ACETYLAMINO-BENZAMIDES AND N-[3-(ACETYLAMINO)PHENYL]-BIPHENYL-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF THE WNT SIGNALLING PATHWAY
  [FR] NOUVEAUX COMPOSÉS

  摘要：

  公开号：

  WO2014147182A3
• 作为产物：
  描述：

  2-氨基-4-硝基甲苯 在 吡啶 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 、 potassium iodide 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 29.5h， 生成 N-(5-amino-2-methylphenyl)-2-(morpholin-4-yl)acetamide
  参考文献：
  名称：

  [EN] SUBSTITUTED N-BIPHENYL-3-ACETYLAMINO-BENZAMIDES AND N-[3-(ACETYLAMINO)PHENYL]-BIPHENYL-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF THE WNT SIGNALLING PATHWAY
  [FR] NOUVEAUX COMPOSÉS

  摘要：

  公开号：

  WO2014147182A3

文献信息

• Aryl nitrogen-containing bicyclic compounds and methods of use
  申请人：Patel F. Vinod

  公开号：US20070054916A1

  公开（公告）日：2007-03-08

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A 1 , A 2 , A 3 , B, R 1 , R 2 , R 3 and R 4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.

  这项发明涉及一类新的化合物，用于预防和治疗蛋白激酶介导的疾病，包括炎症、癌症和相关疾病。这些化合物具有一般的化学式I，其中A1、A2、A3、B、R1、R2、R3和R4在此有定义。因此，该发明还涉及包括该发明的化合物的药物组合物，使用该发明的化合物和组合物预防和治疗激酶介导的疾病的方法，以及用于制备该发明的化合物的中间体和方法。
• Heteroaryl-substituted alkyne compounds and method of use
  申请人：Chaffee C. Stuart

  公开号：US20060217380A1

  公开（公告）日：2006-09-28

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A 1 , A 2 , A 3 , A 4 , R 1 and R 2 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一种新型化合物类别，可用于预防和治疗蛋白激酶介导的疾病，包括炎症、癌症和相关病症。该化合物具有一般式I，其中A1、A2、A3、A4、R1和R2如本文所定义。因此，本发明还涉及包含本发明化合物的制药组合物，使用本发明化合物和组合物预防和治疗激酶介导的疾病的方法，以及用于制备本发明化合物的中间体和过程。
• HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE
  申请人：Chaffee Stuart C.

  公开号：US20100160283A1

  公开（公告）日：2010-06-24

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A 1 , A 2 , A 3 , A 4 , R 1 and R 2 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新的化合物，用于预防和治疗蛋白激酶介导的疾病，包括炎症、癌症和相关疾病。该化合物具有一般式I，其中A1、A2、A3、A4、R1和R2的定义如本文所述。因此，本发明还涉及包括本发明化合物的制药组合物，使用本发明化合物和组合物预防和治疗激酶介导的疾病的方法，以及用于制备本发明化合物的中间体和过程。
• NOVEL COMPOUNDS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160263122A1

  公开（公告）日：2016-09-15

  The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: L A represents an optionally substituted methylene or ethylene group; L B represents —N(H)—C(═0)- or —C(═0)—N(H)—; R 1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —N(R7)(Ci-C6-alkyl) group; R 2 represents an optionally substituted 5- or 6-membered heteroaryl group; R 3 represents an optionally substituted phenyl group.

  本发明涉及一般式（I）所描述和定义的取代N-苯基-杂环基-3-乙酰氨基苯甲酰胺和N-[3-(乙酰氨基)苯基]-苯基-杂环基-羧酰胺，以制备该化合物的方法，用于制备该化合物的中间体化合物，包含该化合物的制药组合物和组合物，以及用于制造治疗或预防癌症等疾病的制药组合物的使用，其中：LA表示可选择取代的亚甲基或乙烯基；LB表示-N(H)-C(═0)-或-C(═0)-N(H)-；R1表示可选择取代的5-至8-成员杂环烷基，4-至10-成员杂环烷基烯基，芳基，杂环芳基或-N(R7)(Ci-C6-烷基)基团；R2表示可选择取代的5-或6-成员杂环基团；R3表示可选择取代的苯基团。
• Compounds
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10130633B2

  公开（公告）日：2018-11-20

  The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: LA represents an optionally substituted methylene or ethylene group; LB represents —N(H)—C(═O)— or —C(═O)—N(H)—; R1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —N(R7)(Ci-C6-alkyl) group; R2 represents an optionally substituted 5- or 6-membered heteroaryl group; R3 represents an optionally substituted phenyl group.

  本发明涉及本文所述和定义的通式(I)的取代的N-(苯基-异芳基)-3-乙酰氨基苯甲酰胺和N-[3-(乙酰氨基)苯基]-苯基-异芳基-甲酰胺，涉及制备所述化合物的方法，涉及制备所述化合物有用的中间化合物，涉及包含所述化合物的药物组合物和组合物，涉及使用所述化合物制造治疗或预防诸如癌症等疾病的药物组合物，其中i.a.: LA 代表任选取代的亚甲基或亚乙基； LB 代表-N(H)-C(═O)-或-C(═O)-N(H)-； R1 代表任选取代的 5 至 8 元杂环烷基、4 至 10 元杂环烯基、芳基、杂芳基或 -N(R7)(Ci-C6-烷基)基团； R2 代表任选取代的 5 或 6 元杂芳基； R3 代表任选取代的苯基。